EXOZYMES INC.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
EXOZ$4.04-5.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets –December 31, 2025 and 2024
CONSOLIDATED BALANCE SHEETS
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | $3,039,343 | $9,719,310 |
| Grants receivable | 517,359 | 737,282 |
| Prepaid expenses and other current assets | 382,886 | 363,790 |
| Total current assets | 3,939,588 | 10,820,382 |
| Property and equipment, net | 764,401 | 882,445 |
| Operating lease right-of-use asset, net | 1,053,641 | 1,331,577 |
| Finance lease right-of-use asset, net | 108,682 | - |
| Tax receivable | 105,205 | - |
| Total assets | $5,971,517 | $13,034,404 |
| LIABILITIES AND EQUITY | ||
| Accounts payable | $1,235,337 | $924,252 |
| Due to affiliates | 5,330 | 178,966 |
| Operating lease liabilities – Current | 281,979 | 230,027 |
| Finance lease liabilities – Current | 44,255 | - |
| Total current Liabilities | 1,566,901 | 1,333,245 |
| Deferred grant reimbursement | 90,365 | 123,579 |
| Operating lease liabilities - Long term | 852,575 | 1,156,805 |
| Finance lease liabilities - Long term | 64,427 | - |
| Total liabilities | $2,574,268 | $2,613,629 |
| Stockholders’ Equity: | ||
| Preferred stock, $0.000001 par value, 5,000,000 shares authorized; no shares issued and outstanding on December 31, 2025, and December 31, 2024, respectively. | - | - |
| Common shares, 100,000,000 authorized shares at $0.000001; 8,406,681 and 8,367,810 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | 8 | 8 |
| Additional Paid-in-capital | 24,501,933 | 22,366,725 |
| Accumulated (deficit) | (21,104,692) | (11,945,958) |
| Total stockholders’ equity | 3,397,249 | 10,420,775 |
| Total liabilities and stockholders’ equity (deficit) | $5,971,517 | $13,034,404 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.